Healthcare Central

  • Chiesi Wins FDA Approval for First Drug to Treat Ultra-Rare Enzyme Deficiency

    Chiesi Wins FDA Approval for First Drug to Treat Ultra-Rare Enzyme Deficiency Chiesi drug Lamzede is an engineered version of an enzyme that’s lacking in patients with the rare disease alpha-mannosidosis. FDA approval of the Chiesi drug comes about five years after European regulators authorized the product. Information Courtesy By: Frank Vinluan, #HealthcareNews #Healthcare |…

  • Karuna Picks Up Kidney Drugs for Chance to Challenge Boehringer Ingelheim in the Brain

    Karuna Picks Up Kidney Drugs for Chance to Challenge Boehringer Ingelheim in the Brain Karuna Therapeutics has licensed two small molecules that shuttering Goldfinch Bio had developed for kidney disorders. These compounds target a pathway that could also treat neurological disorders, giving clinical-stage Karuna the opportunity to compete against a drug candidate from Boehringer Ingelheim.…

Got any book recommendations?

Get In Touch